These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1456 related articles for article (PubMed ID: 30779077)

  • 1. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
    Gao BB; Wang SX
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
    Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
    Shi H; Pu J; Zhou XL; Ning YY; Bai C
    Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
    Zhou Y; Li S; Li J; Wang D; Li Q
    Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
    Cai Y; Dong ZY; Wang JY
    Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of lncRNA-BLACAT1 on drug resistance of non-small cell lung cancer cells in DDP chemotherapy by regulating cyclin D1 expression.
    Ju ZS; Sun B; Bao D; Zhang XF
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9465-9472. PubMed ID: 33015788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA HULC promotes non-small cell lung cancer cell proliferation and inhibits the apoptosis by up-regulating sphingosine kinase 1 (SPHK1) and its downstream PI3K/Akt pathway.
    Liu L; Zhou XY; Zhang JQ; Wang GG; He J; Chen YY; Huang C; Li L; Li SQ
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8722-8730. PubMed ID: 30575912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA BX357664 inhibits the proliferation and invasion of non-small cell lung cancer cells.
    Yang J; Du YM; Li B
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):660-669. PubMed ID: 30720174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
    Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
    Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling.
    Tang Y; Xiao G; Chen Y; Deng Y
    Anticancer Drugs; 2018 Sep; 29(8):725-735. PubMed ID: 29916897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA ASAP1-IT1 promotes cell proliferation, invasion and metastasis through the PTEN/AKT signaling axis in non-small cell lung cancer.
    Zhang L; Shi SB; Zhu Y; Qian TT; Wang HL
    Eur Rev Med Pharmacol Sci; 2018 Jan; 22(1):142-149. PubMed ID: 29364481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-122-5p promotes the development of non-small cell lung cancer via downregulating p53 and activating PI3K-AKT pathway.
    Fan X; Wu X
    J BUON; 2019; 24(1):273-279. PubMed ID: 30941980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly expressed long non-coding RNA CRNDE promotes cell proliferation through PI3K/AKT signalling in non-small cell lung carcinoma.
    Liu XX; Xiong HP; Huang JS; Qi K; Xu JJ
    Clin Exp Pharmacol Physiol; 2017 Aug; 44(8):895-902. PubMed ID: 28477368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR.
    Li B; Ding CM; Li YX; Peng JC; Geng N; Qin WW
    Oncol Rep; 2018 Mar; 39(3):1227-1234. PubMed ID: 29344640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
    Gong T; Cui L; Wang H; Wang H; Han N
    J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
    Lu C; Shan Z; Hong J; Yang L
    Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel long non-coding RNA LBX2-AS1 indicates poor prognosis and promotes cell proliferation and metastasis through Notch signaling in non-small cell lung cancer.
    Tang LX; Su SF; Wan Q; He P; Xhang Y; Cheng XM
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(17):7419-7429. PubMed ID: 31539129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of Long Noncoding RNA_GAS5 Suppresses Cell Proliferation and Metastasis in Laryngeal Cancer via Regulating PI3K/AKT/mTOR Signaling Pathway.
    Liu W; Zhan J; Zhong R; Li R; Sheng X; Xu M; Lu Z; Zhang S
    Technol Cancer Res Treat; 2021; 20():1533033821990074. PubMed ID: 33641529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA HOXA-AS2 regulates microRNA-216a-5p to promote malignant progression of non-small cell lung cancer.
    Cui TJ; Lin GS; Dai YM; Zheng JP; Chen Z; Chen Q; Zheng Y; Lin X
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(3 Suppl):264-273. PubMed ID: 31389597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pentraxin 3 acts as a functional effector of Akt/NF-κB signaling to modulate the progression and cisplatin-resistance in non-small cell lung cancer.
    Li Y; Song X; Niu J; Ren M; Tang G; Sun Z; Kong F
    Arch Biochem Biophys; 2021 Apr; 701():108818. PubMed ID: 33617838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.